Literature DB >> 10493969

Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines.

U Pohl1, W Wick, J Weissenberger, J P Steinbach, J Dichgans, A Aguzzi, M Weller.   

Abstract

Glial fibrillary acidic protein (GFAP)-v-src transgenic mice develop spontaneous gliomas with a high incidence of malignant progression. We characterize the first glial cell line derived from v-src transgenic mice, Tu-2449 in comparison with a virally induced murine glioma, SRB-10, and a spontaneous murine glioma, P497. Doubling times were lowest, as clonogenicity in soft agar was highest for Tu-2449, and to a lesser degree, Tu-2449 cells formed spheroids and showed migratory behaviour and invaded fetal rat brain aggregates. BCL-2 and BAX expression were lower in Tu-2449 and P497 than in SRB-10 cells. Only Tu-2449 cells accumulated p53 protein in response to genotoxic stress. Tu-2449 and SRB-10 cells that showed low CD95 expression were resistant to CD95 ligand (CD95L)-induced apoptosis unless coexposed to CD95L and inhibitors of RNA or protein synthesis. A chemosensitivity profile revealed Tu-2449 to be rather chemoresistant. Tu-2449 thus displays growth characteristics and patterns of resistance to apoptosis similar to those of other mouse and human glioma cell lines and may therefore become a valuable tool to evaluate new therapies for malignant gliomas in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493969     DOI: 10.3892/ijo.15.4.829

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  13 in total

1.  Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.

Authors:  Kader Yagiz; Tiffany T Huang; Fernando Lopez Espinoza; Daniel Mendoza; Carlos E Ibañez; Harry E Gruber; Douglas J Jolly; Joan M Robbins
Journal:  Neuro Oncol       Date:  2016-05-10       Impact factor: 12.300

2.  Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.

Authors:  Juraj Hlavaty; Gerrit Jandl; Melissa Liszt; Helga Petznek; Marielle König-Schuster; Jenny Sedlak; Monika Egerbacher; Jakob Weissenberger; Brian Salmons; Walter H Günzburg; Matthias Renner
Journal:  J Neurooncol       Date:  2010-07-11       Impact factor: 4.130

3.  Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.

Authors:  Tiffany T Huang; Shraddha Parab; Ryan Burnett; Oscar Diago; Derek Ostertag; Florence M Hofman; Fernando Lopez Espinoza; Bryan Martin; Carlos E Ibañez; Noriyuki Kasahara; Harry E Gruber; Daniel Pertschuk; Douglas J Jolly; Joan M Robbins
Journal:  Hum Gene Ther       Date:  2015-01-19       Impact factor: 5.695

4.  Establishment and partial characterization of a continuous human malignant glioma cell line: NG97.

Authors:  M C Grippo; P F Penteado; E F Carelli; M A Cruz-Höfling; L Verinaud
Journal:  Cell Mol Neurobiol       Date:  2001-08       Impact factor: 5.046

5.  STAT3 silencing inhibits glioma single cell infiltration and tumor growth.

Authors:  Maike Priester; Ekaterini Copanaki; Vida Vafaizadeh; Sandra Hensel; Christian Bernreuther; Markus Glatzel; Volker Seifert; Bernd Groner; Donat Kögel; Jakob Weissenberger
Journal:  Neuro Oncol       Date:  2013-03-13       Impact factor: 12.300

6.  Is the immune response a friend or foe for viral therapy of glioma?

Authors:  Hideho Okada; Stephen H Thorne
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

7.  Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.

Authors:  Derek Ostertag; Karin K Amundson; Fernando Lopez Espinoza; Bryan Martin; Taylor Buckley; Ana Paula Galvão da Silva; Amy H Lin; David T Valenta; Omar D Perez; Carlos E Ibañez; Ching-I Chen; Pär L Pettersson; Ryan Burnett; Veronika Daublebsky; Juraj Hlavaty; Walter Gunzburg; Noriyuki Kasahara; Harry E Gruber; Douglas J Jolly; Joan M Robbins
Journal:  Neuro Oncol       Date:  2011-11-09       Impact factor: 12.300

8.  Morphological characterization of a human glioma cell l ine.

Authors:  Camila Ml Machado; André Schenka; José Vassallo; Wirla Msc Tamashiro; Estela M Gonçalves; Selma C Genari; Liana Verinaud
Journal:  Cancer Cell Int       Date:  2005-05-10       Impact factor: 5.722

9.  Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment.

Authors:  Kirsten Ridder; Alexandra Sevko; Janina Heide; Maria Dams; Anne-Kathleen Rupp; Jadranka Macas; Julia Starmann; Marc Tjwa; Karl H Plate; Holger Sültmann; Peter Altevogt; Viktor Umansky; Stefan Momma
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

10.  Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.

Authors:  Kei Hiraoka; Akihito Inagaki; Yuki Kato; Tiffany T Huang; Leah A Mitchell; Shuichi Kamijima; Masamichi Takahashi; Hiroshi Matsumoto; Katrin Hacke; Carol A Kruse; Derek Ostertag; Joan M Robbins; Harry E Gruber; Douglas J Jolly; Noriyuki Kasahara
Journal:  Neuro Oncol       Date:  2017-07-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.